Heparin-bonded circuits: Clinical outcomes and costs

Perfusion

Volumn 13, Issue 3, 1998, Pages 192-204

  Mahoney, C Brown ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN;

ARTICLE; CARDIOPULMONARY BYPASS; COST BENEFIT ANALYSIS; COST CONTROL; EXTRACORPOREAL OXYGENATION; HEALTH CARE COST; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0345724177     PISSN: 02676591     EISSN: None     Source Type: Journal    
DOI: 10.1177/026765919801300307     Document Type: Article

References (127)

1. Gipe B, Harris S, Rosenberg M. A new method for direct cost analysis. Southwest Crit Care Assoc 1995; 1: 1-16.
2. Drummond M, Stoddart G, Torrance G. Methods for evaluation of health care programs. New York: Oxford Medical Publications, 1987.
3. Debois W, Brennan R, Wein E, Isom O, Gold J. Centrifugal pumping: the patient outcome benefits following coronary artery bypass surgery. J Extracorp Technol 1995; 27: 77-80.
4. American Heart Association. Heart and stroke fact: 1996 statistical supplement. Dallas, TX: American Heart Association, 1996.
5. Gibbon J Jr. Application of a mechanical heart and lung apparatus to cardiac surgery. Minn Med 1954; 37: 171-85.
6. Gravlee G. Heparin-coated cardiopulmonary bypass circuits. J Cardiothorac Vasc Anesth 1994; 8: 213-22.
7. Daniel S. Review on the multifactorial aspects of bioincompatibility in CPB. Perfusion 1996; 11: 246-55.
8. Korn R, Fisher C, Livingston E et al. The effects of Carmeda bioactive surface on human blood components during simulated extracorporeal circulation. J Thorac Cardiovasc Surg 1996; 111: 1073-84.
9. Edmunds L Jr. Blood surface interactions during cardiopulmonary bypass. J Card Surg 1993; 8: 404-10.
10. Ratner B. The blood compatibility catastrophe. J Biomed Mater Res 1993; 27: 283-87.
11. Svennig J, Froysaker T. Complement activation during extracorporeal circulation. In vitro comparison of Duraflo II heparin-coated and uncoated oxygenator circuits. J Thorac Cardiovasc Surg 1993; 106: 466-72.
12. Gorman J III, Edmunds L Jr. Blood anesthesia for cardiopulmonary bypass. J Card Surg 1995; 10: 270-79.
13. Kirklin J, Westaby S, Blackstone E et al. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1983; 86: 845-57.
14. McLean J. The discovery of heparin. Circulation 1959; 19: 75-78.
15. Best CH. Preparation of heparin and its use in the first clinical cases. Circulation 1959; 19: 79-86.
16. Chargraff E, Olson K. Studies on the chemistry of blood coagulation. VI. Studies on the action of heparin and other anti-coagulant effect in vivo. J Biol Chem 1938; 125: 671-76.
17. Aldea G, Doursounian P, O'Gara P et al. Heparin-bonded circuits with a reduced anticoagulation protocol in primary CABG: a prospective, randomized study. Ann Thorac Surg 1996; 62: 410-18.
18. Fosse E, Moen E, Johnson E et al. Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass. Ann Thorac Surg 1994; 58: 472-77.
19. Wendel H, Heller W, Hoffmeister H. Pathway of platelet protection in heparin-coated devices and its significance for cardiac surgery. Trans Soc Biomat 1995; 21: 28.
20. Gu Y, van Oeveren W, van der Kamp K, Akkerman C, Boonstra P, Wildevuur CRH. Heparin-coating of extracorporeal circuits reduces thrombin formation in patients undergoing cardiopulmonary bypass. Perfusion 1991; 6: 221-25.
21. Pekna M, Hagman L, Halden E et al. Complement activation during cardiopulmonary bypass: Effects of immobilized heparin. Ann Thorac Surg 1994; 22: 421-24.
22. Gorman R, Ziats N, Gikakis N et al. Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg 1996; 111: 1-12.
23. Ovrum E, Mollnes T, Fosse E et al. Complement and granulocyte activation in two different types of heparinized extracorporeal circuits. J Thorac Cardiovasc Surg 1995; 110: 1623-32.
24. Jansen P, teVelthuis H, Huybregts R et al. Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin coated circuits. J Thorac Cardiovasc Surg 1995; 110: 829-34.
25. Boonstra P, Gu Y, Akkerman C, Haan J, Huyzen R, van Oeveren W. Heparin coating of an extracorporeal circuit partly improves hemostatis after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1994; 107: 289-92.
26. Ellwood P. Shattuck lecture - outcomes management: a technology of patient experience. N Engl J Med 1988; 318: 1549-56.
27. Donabedian A. The methods and findings of quality assessment and monitoring: an illustrated analysis. Volume 3. Ann Arbor, MI: Health Administration Press, 1985.
28. Relman A. Assessment and accountability: the third revolution in medical care. N Engl J Med 1988; 319: 1220-22.
29. Eddy DM, Hasselblad V, Schachter R. Meta-analysis by the confidence profile method: the statistical synthesis of evidence. Boston, MA: Academic Press, 1992.
30. Edmunds L. Surface-bound heparin: panacea or peril? Ann Thorac Surg 1994; 58: 285-86.
31. Edmunds L. Why cardiopulmonary bypass makes patients sick: strategies to control the blood-synthetic surface interface. Adv Cardiac Surg 1995; 6: 131-67.
32. von Segessor L, Weiss B, Pasic M et al. Risk and benefits of low systemic heparinization during open heart operations. Ann Thorac Surg 1994; 58: 391-98.
33. Borowiec J, Thelin S, Bagge L, van der Linden J, Thorno E, Hansson H. Heparin-coated cardiopulmonary bypass circuits in coronary artery surgery - a clinical study. J Extracorp Technol 1990; 22: 86-90.
34. Borowiec J, Thelin S, Bagge L, Nilsson L, Venge P, Hansson H. Heparin-coated circuits reduce activation of granulocytes during cardiopulmonary bypass: a clinical study. J Thorac Cardiovasc Surg 1992; 104: 642-47.
35. Jones D, Hill R, Vasilakis A et al. Use of heparin-coated cardiopulmonary bypass. Ann Thorac Surg 1993; 56: 566-68.
36. Ladowski J, Schatlein M, Peterson A, Deschner W, Matheis R, Ellenwood M. Clinical heparin coated cardiopulmonary bypass: reduction of systemic heparin requirements for redo cardiac surgery. ASAIO J 1996; 42: 34-36.
37. Laub G, Clancy R, Chen C et al. The impact of Carmeda bound cardiopulmonary bypass circuits on clinical outcome: a double-blind, randomized trial [Abstract]. In: Pathophysiology and techniques of cardiopulmonaiy bypass. San Diego: 1996.
38. Sellevold OF, Berg TM, Rein KA, Levang OW, Iversen OJ, Bergh K. Heparin-coated circuit during cardiopulmonary bypass. A clinical study using closed circuit, centrifugal pump and reduced heparinization. Acta Anaesthesiol Scand 1994; 38: 372-79.
39. Von Segesser L, Garcia E, Turina M. Low dose heparin versus full-dose heparin with high dose aprotinin during cardiopulmonary bypass. Tex Heart Inst J 1993; 20: 28-32.
40. Wagner W, Johnson P, Thompson K, Marrone G. Heparin-coated cardiopulmonary bypass circuits: hemostatic alterations and postoperative blood loss. Ann Thorac Surg 1994; 58: 734-41.
41. Moen O, Fosse E, Brockmeier V et al. Disparity in blood activation by two different heparin-coated cardiopulmonary bypass systems. Ann Thorac Surg 1995; 60: 1317-23.
42. Knoch M, Kollen B, Dietrich G, Muller E, Mottaghy K, Lennartz H. Progress in veno-venous long-term bypass techniques for the treatment of ARDS. Int J Artif Organs 1992; 15: 1013-108.
43. Baufreton C, Le Besnerais P, Jansen P, Mazzucotelli J, Wildevur C, Loisance D. Clinical outcome after coronary surgery with heparin-coated extracorporeal circuits for cardiopulmonary bypass. Perfusion 1996; 11: 437-43.
44. Rigby K, Crockett A, Silagy C. Can resource use be extracted from randomized controlled trials to calculate costs? A review of smoking cessation interventions in general practice. Int J Technol Assess Health Care 1996; 12: 554-72.
45. Thacker S. Meta-analysis: a quantitative approach to research integration. J Am Med Assoc 1988; 259:1685-89.
46. Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers T. Meta-analyses of randomized controlled trials. N Engl J Med 1987; 316: 450-55.
47. Cooper H, Hedges L. The handbook of research synthesis. New York: Russell Sage Foundation, 1994.
48. Borowiec J, Bylock A, van der Linden J, Thelin S. Heparin coating reduces blood cell adhesion to arterial filters during coronary bypass: a clinical study. Ann Thorac Surg 1993; 55: 1540-45.
49. Jansen P, Baufreton C, Le Besnerais P, Loisance D, Wildevuur C. Heparin-coated circuits and aprotinin prime for coronary artery bypass grafting. Ann Thorac Surg 1996; 61: 1363-66.
50. Jones D, Hill R, Vasilakis A et al. Use of heparin-coated cardiopulmonary bypass. Ann Thorac Surg 1993; 56: 566-68.
51. Muehrcke D, McCarthy P, Kottke-Marchant K et al. Biocompatibility of heparin-coated extracorporeal bypass circuits: a randomized, masked clinical trial. J Thorac Cardiovasc Surg 1996; 112: 472-83.
52. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
53. Reeder GS. Angioplasty and the cost of myocardial revascularization: has its promise been fulfilled? Int J Cardiol 1987; 15: 287-92.
54. Goldman L, Gordon D, Rifkind B et al. Cost and health implications of cholesterol lowering. Circulation 1992; 85: 1960-68.
55. Federal Register, US Government Printing Office, 1996.
56. O'Brien B, Rushby J. Outcome assessment in cardiovascular cost-benefit studies. Am Heart J 1990; 119: 740-48.
57. Eisenberg JM. Clinical economics: a guide to the economic analysis of clinical practices. J Am Med Assoc 1989; 262: 2879-86.
58. Luce BR, Elixhauser A. Estimating costs in the economic evaluation of medical technologies. Int J Tech Assess in Health Care 1990; 6: 57-75.
59. Mahoney CB. Pacing and outcomes: the economic implications. In: Geisler E, Heller O eds. Managing technology in health care. Norwell, MA: Kluwer Academic, 1996: 69-102.
60. Aranki S, Adams D, Rizzo R et al. Femoral veno-arterial extracorporeal life support with minimal or no heparin. Ann Thorac Surg 1993; 56: 149-55.
61. Bennett J, Hill J, Long W et al. Biocompatible circuits: an adjunct to non-cardiac extracorporeal cardiopulmonary support. J Extracorp Technol 1992; 24: 6-11.
62. Bennett J, Parsons J. Heparin-free cardiopulmonary support, utilizing a Carmeda-coated circuit, for a patient with pulmonary hemorrhage and multiple trauma. American Society of Extracorporeal Technology Proceedings, 1993.
63. Bianchi JJ, Swartz MT, Raithel SC et al. Initial clinical experience with centrifugal pumps coated with the Carmeda process. ASAIO J 1992; 38: 143-46.
64. Biarent D, Bouton J M, Vanderrieviere J, DeMunter C, Desay H. Extracorporeal life support complications with heparin-coated circuits in children. Cardiol Young 1995; 5: S1869.
65. Bindslev L, Ecklund J, Norlander O et al. Treatment of acute respiratory failure by extracorporeal carbon dioxide elimination performed with a surface heparinized artificial lung. Anesthesiology 1987; 67: 117-20.
66. Bindslev L. Adult ECMO performed with surface-heparinized equipment. ASAIO Trans 1988; 34: 1009-1013.
67. Bindslev L, Bohm C, Jolin A et al. Extracorporeal carbon dioxide removal performed with surface-heparinized equipment in patients with ARDS. Acta Anaesthesiol Scand Suppl 1991; 95: 125-30.
68. Belboul A, Al-Khaja N, Gudmundsson M et al. The influence of heparin-coated and uncoated extracorporeal circuits on blood rheology during cardiac surgery. J Extracorp Technol 1993; 25: 40-46.
69. Cardoso P, Yamazaki F, Keshaujee S et al. A reevaluation of heparin requirements for cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991; 101: 153-60.
70. Cederholm I, Johnson M, Carnstam B, Ljunghusen O, Olin C. Heparin coated circuit for cardiopulmonary bypass. 44th Annual Meeting of the Scandinavian Association for Thoracic Surgery, Orebro, Sweden, 1995; 37:
71. Contino J, Follette D, Berkoff H, Pollock M, Bogren H, Wisner D. Use of Carmeda-coated femoral-femoral bypass during repair of traumatic aortic pseudoaneurysms. Arch Surg 1994; 129: 933-37.
72. Dowling R, Brown M, Whittington R, Quinlan J, Armitage J. Clinical cardiopulmonary bypass without systemic anticoagulation. Ann Thorac Surg 1993; 56: 1176-178.
73. Elgue G, Blomback M, Olsson P, Riesenfeld J. The mechanism of coagulation inhibition on surfaces with end point immobilized heparin. Stockholm: The Department of Experimental Surgery, Karolinska Hospital, 1993.
74. Fjalldal O, Torfason B, Onundarson PT et al. Prolonged total extracorporeal lung assistance without systemic heparinization. Acta Anaesthesiol Scand 1993; 37: 115-20.
75. Golding L. Heparin-bonded extracorporeal life support systems. ASAIO J 1996; 42: 16-18.
76. Gravlee G, Davis R, Utley J. Cardiopulmonary bypass: principles and practice. Baltimore, MD: Williams & Wilkins, 1993.
77. Grossi E, Galloway A, Aguinaga M et al. Covalently bonded heparin bypass circuits reduce complement activation and cytokine production in pediatric patients. [Draft 1995.]
78. Gu Y, van Oeveran W, Akkerman C et al. Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1993; 55: 917-22.
79. Hatori N, Yoshizu H, Haga Y et al. Biocompatibility of heparin-coated membrane oxygenator during cardiopulmonary bypass. Artif Organs 1994; 18: 904-10.
80. Heller W. Comparative studies on the haemo and biocompatibility of a heparin-coated system in aortocoronary bypass surgery. Cardiothorac Surg Symposium, 1995.
81. Hollingsed M, Hill R, Wittig R, Murray G, Stullken E. Heparin coated cardiopulmonary bypass: a clinical case incorporating a standard cardiotomy. Perfusion 1992; 7: 305-14.
82. Horikoshi S, Nakano M, Hashimoto K et al. Alterations in coagulation, fibrinolysis and complement during cardiopulmonary bypass with a heparin-coated oxygenator. Artif Organs Today 1994; 3: 239-52.
83. Iezzoni L ed. Risk adjustment for measuring health care outcomes. Ann Arbor, MI: Health Administration Press, 1994.
84. Jolin A, Eden E, Berggren H et al. Management of a giant intracranial aneurysm using surface heparinized extracorporeal circulation and controlled deep hypothermic low flow perfusion. A case report. Acta Anaesthesiol Scand 1993; 37: 756-60.
85. Kawahito K, Ino T, Adachi H, Ide H, Mizuhara A, Yamaguchi A. Heparin-coated percutaneous cardiopulmonary support for the treatment of circulatory collapse after cardiac surgery. ASAIO J 1994; 40: 972-76.
86. Kawahito K, Ino T, Adachi H et al. Controlling the blood coagulation on the blood contacting surface of the assist devices - perfusion with heparin-coated equipment with low dose systemic heparinization. Jpn J Artif Organs 1994; 23: 612-17.
87. Khuri SF, Valeri R, Losclazo J et al. Heparin causes platelet dysfunction and indices of fibrinolysis before cardiopulmonary bypass. Ann Thorac Surg 1995; 60: 1008-14.
88. Koul B, Wetterberg T, Ohqvist G, Olsson P. Veno-venous extracorporeal membrane oxygenation with heparin-coated system in adult respiratory distress syndrome. Scand J Thorac Cardiovasc Surg 1991; 25: 199-206.
89. Larm O, Lins LE, Olsson P. An approach to antithrombosis by surface modification. Progress in Artificial Organs. Cleveland, OH: ISAIO Press, 1986.
90. Larsson R, Larm O, Olsson P. The search for thromboresistance using immobilized heparin: blood in contact with natural and artificial surfaces. Ann NY Acad Sci 1987; 516: 102-15.
91. Liu LS, Ito Y, Imanishi Y. Synthesis and antithrombogenicity of heparinized polyurethanes with intervening spacer chains of various kinds. Biomaterials 1991; 12: 390-96.
92. Miyamoto Y, Nakano S, Takano H, Matsuda H. Beneficial effects of protease inhibitor (Nafamostat Mesilate) and heparin-coated circuit on hemostasis and inflammatory response during open heart surgery. Jpn J Artif Organs 1994; 23: 606-11.
93. Moen O, Fosse E, Andersson C, Molness T, Hogasen K, Venge P. Heparin-coated surfaces reduce complement and granulocyte activation during CPB - a comparison of Bentley Duraflo II and the Carmeda Bioactive Surface (CBAS). 44th Ann Meeting Scand Assoc Thoracic Surg, Orebro, Sweden, 1995; 1: 28.
94. Moines TE, Videm V, Gotze O, Harboe M, Oppermann M. Formation of C5a during cardiopulmonary bypass: inhibition by precoating with heparin. Ann Thorac Surg 1991; 52: 92-97.
95. Mottaghy K, Oedekoven B, Schaich-Lester D, Pöppel K, Kupper W. Applications of surfaces with end point attached heparin to extracorporeal circulation with membrane lungs. ASAIO Trans 1989; 35: 146-52.
96. Moulton M, Creswell L, Mackey M, Cox J, Rosenbloom M. Re-exploration for bleeding is a risk factor for adverse outcomes after cardiac operations. J Thorac Cardiovasc Surg 1996; 11: 1037-46.
97. Nilsson L, Peterson C, Venge P, Borowiec J, Thelin S. Eosinophil granule proteins in cardiopulmonary bypass with and without heparin coating. Ann Thorac Surg 1995; 59: 713-16.
98. Nilsson U, Larm O, Nilsson B, Storm K, Elwing H, Nilsson Ekdahl K. Modification of the complement binding properties of polystyrene: effects of endpoint heparin attachment. Scand J Immunol 1993; 37: 349-54.
99. Olsson P. Non-thrombogenic systems for extracorporeal gas exchange. Int J Artif Organs 1993; 16.
100. Olsson P, Larm O. Biologically active heparin coating in medical devices. Int J Artif Organs 1991; 14: 453-56.
101. Ovrum E. Eosinophil granulocyte activation and heparin-coated cardiopulmonary bypass [Letter]. Ann Thorac Surg 1996; 61: 1038-40.
102. Ovrum E, Mollnes T, Fosse E et al. High and low heparin dose with heparin-coated cardiopulmonary bypass circuits: activation of complement and granulocytes. Ann Thorac Surg 1995; 60: 1755-61.
103. 2-removal with a heparin coated artificial lung. Intensive Care Med 1988; 14: 578-84.
104. Pradhan M, Fleming J, Nkere U, Arnold J, Wildevuur C, Taylor K. Clinical experience with heparin-coated cardiopulmonary bypass circuits. Perfusion 1991; 6: 235-42.
105. Rossaint R, Slama K, Lewandowski K et al. Extracorporeal lung assist with heparin-coated systems. Int J Artif Organs 1992; 15: 29-34.
106. Shigemitsu O, Hadama T, Takasaki H et al. Biocompatibility of a heparin-bonded membrane oxygenator (Carmeda Maxima) during the first 90 minutes of cardiopulmonary bypass: clinical comparison with the conventional system. Artif Organs 1994; 8: 936-41.
107. Shumway R, Lowe N, Wirth L, Riesenfeld J, Carmeda A, Olsson P. Functional characteristic determination of an immobilized bioactive heparin surface: a direct biological assay. Proc Am Acad Cardiovasc Perfusion 1990; 11: 43-46.
108. Steinberg B, Grossi E, Schwartz D. Heparin bonding of bypass circuits reduces cytokine release during cardiopulmonary bypass. Ann Thorac Surg 1995; 60: 525-29.
109. Svenmarker S, Sandstrom E, Karlsson T et al. Clinical benefit of the heparin-coated surface in cardiopulmonary bypass. 44th Annual Meeting of the Scandinavian Association for Thoracic Surgery, Orebro, Sweden, 1995.
110. te Velthuis H, Jansen P, Hack C, Eijsman L, Wildevuur C. Specific complement inhibition with heparin-coated extracorporeal circuits. Ann Thorac Surg 1996; 61: 1153-57.
111. Thelin S, Bylock A, Bagge L et al. Heparin-coated cardiopulmonary bypass sets during surgery - a clinical study. J Extracorp Technol 1990; 22: 6.
112. Tong D, Rolfs M, Hsu L. Evaluation of Duraflo II heparin imobilized cardiopulmonary bypass circuits. ASAIO Trans 1990; 36: 654-56.
113. Utley J. Pathophysiology of cardiopulmonary bypass: current issues. J Card Surg 1990; 5: 177-89.
114. van der Kamp K, van Oeveren W. Contact, coagulation and platelet interaction with heparin-treated equipment during heart surgery. Int J Artif Organs 1993; 16: 836-42.
115. Videm V, Mollnes TE, Garred P, Svennevig JL. Biocompatibility of extracorporeal circulation. In vitro comparison of heparin-coated and uncoated oxygenator circuits. J Thorac Cardiovasc Surg 1991; 101: 654-56.
116. Videm V, Svennevig J, Fosse E, Semb G, Osterud A, Molness T. Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations. J Thorac Cardiovasc Surg 1992; 103: 806-13.
117. von Segesser LK, Weiss BM, Garcia E, Gallino AS, Turina M. Reduced blood loss and transfusion requirements with low systemic heparinization: preliminary clinical results in coronary artery revascularization. Eur J Cardiothorac Surg 1990; 4: 639-43.
118. von Segesser LK, Weiss BM, Bisang B, Leskosek B, Turina M. Ventricular assist with heparin surface coated devices. ASAIO Trans 1991; 67: H278-H279.
119. von Segesser LK, Weiss BM, Gallino A et al. Superior hemodynamics in left heart bypass without systemic heparization. Eur J Cardiothorac Surg 1990; 4: 3884-89.
120. von Segesser LK, Lachat M, Gallino A et al. Performance characteristics of centrifugal pumps with heparin surface coating. Thorac Cardiovasc Surg 1990; 34: 224-28.
121. von Segesser LK, Wiss BM, Leskosek B, von Feiten A, Pei P, Turina M. Experimental evaluation of heparin-coated cardiopulmonary bypass equipment with low systemic heparinization and high dose aprotinin. Thorac Cardiovasc Surg 1991; 39: 251-56.
122. Weerwind P, Maessen J, van Tits L et al. Influence of Duraflo II heparin-treated extracorporeal circuits on the systemic inflammatory response in patients having coronary bypass. J Thorac Cardiovasc Surg 1995; 110: 1633-41.
123. Weiss B, von Segesser L, Vetter W, Gautsch K, Pasch T. Heparin-coated left heart bypass: renal function and hormonal response. Int J Artif Organs 1991; 14: 792-99.
124. Williams D, Dembitsky W. Prolonged extracorporeal support for ARDS using surface heparinised equipment. Chest 1992; 102: 968-70.
125. Yamada H, Kudoh I, Hirose Y, Toyoshima M, Abe H, Kurahashi K. Heparin-coated circuits reduce the formation of TNF during cardiopulmonary bypass. Acta Anaesthesiol Scand 1996; 40: 311-17.
126. Yamaguchi AMD, Ino TMD, Adachi HMD et al. Biocompatibility of heparin-coated circuits: alterations in cytokines, leukocyte and platelet activation during cardiopulmonary bypass in human. Jpn J Artif Organs 1995; 24: 886-89.
127. Young J, Kisher C, Doty D. Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and appearance of fibrin monomer. Ann Thorac Surg 1978; 26: 231-40.